CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for CHO Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

CHO Pharma Inc
7F, Building C, No. 99, Lane 130
Section 1, Academia Road, Nangang Distri
Phone: +886 226558059p:+886 226558059 TAIPEI, 115  Taiwan Ticker: 65866586
Business Summary
CHO PHARMA INC. is principally engaged in the development of new drugs related to sugar molecules. The company’s technology and development can be divided into eight categories according to its patent features, including homogeneous antibody drugs, monoclonal antibodies of cancers and immune-related diseases, carbohydrate-related vaccines and drugs, anti-influenza drugs, the development and application of Saccharin tablets, the development and application of sugar probes, the synthesis identification development and application of sugar molecular, as well as the derivative patents of innovation development plans.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Chao-LongChen 2/24/2022 12/27/2017
Finance Manager, Corporate Governance Officer I-PeiChou 3/16/2023 3/28/2016
General Manager, Chief Information Security Officer Chung-YiWu 5/18/2023 3/7/2019
6 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 214,011,000 (As of 12/31/2023)
Shareholders: 9,648
Stock Exchange: TPO
Fax Number: +886 226558069


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 18, 2024